Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.

Lipids Health Dis · 2009 · PMC2803170 · PMID 20017910

Europe PMC DOI

hedged sentence

0.0790

closest p · 1.6× alpha

0.0790

boldest claim

The sentences

showed a trendp = 0.079so close (0.05 < p ≤ 0.1)

Combination therapy showed a trend towards a greater reduction in triglycerides (-25.4% with combination versus -14.5% with atorvastatin, p = 0.079), although there was no significant difference between the two study interventions in terms of the improvement in the TC:HDL ratio (-29.0% with combination versus -28.7% with atorvastatin, p = 0.904).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.